CAS: 1236033-03-6; (R)-3-Cyclopentyl-3-(4-(7-(Hydroxymethyl)-7H-Pyrrolo[2,3-D]Pyrimidin-4-yl)-1H-Pyrazol-1-yl)Propanenitrile
该化合物是一种复杂的有机化合物,其独特的结构特征具有其独特性,包括一个环丙烯环和环丙酰胺.该化合物展示了一系列典型的杂交化合物化学特性,例如由于硝酸和氢氧甲基组的存在而可能发生再活动.它的立体化学学,通过(R)项的指定表明,它提出了可能影响其生物活动和相互作用的具体空间安排.环戊基环丙基化合物的存在有助于其水恐特性,可能影响生物系统中的溶解性和渗透性.该化合物可能对医药化学具有兴趣,特别是其潜在的药用用途,因为具有类似结构的化合物往往表现出重要的生物活动.然而,必须对其具体特性进行详细研究,包括溶性,稳定性和生物影响其作用及其作用机制进行充分理解.
- 英文名称(R)-3-Cyclopentyl-3-(4-(7-(Hydroxymethyl)-7H-Pyrrolo[2,3-D]Pyrimidin-4-yl)-1H-Pyrazol-1-yl)Propanenitrile
- 中文名称1H-吡唑-1-丙腈,β-环戊基-4-[7-(羟基甲基)-7H-吡咯并[2,3-D]嘧啶-4-基]-,(βR)-
- IUPAC名称(R)-3-Cyclopentyl-3-(4-(7-(hydroxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile
- 其它别名(3R)-3-Cyclopentyl-3-[4-[7-(Hydroxymethyl)Pyrrolo[2,3-D]Pyrimidin-4-Yl]Pyrazol-1-Yl]Propanenitrile; 1H-Pyrazole-1-Propanenitrile, β-Cyclopentyl-4-[7-(Hydroxymethyl)-7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl]-,(βr)-; Ruxolitinib N-Methanol; Ruxolitinib Impurity 4; Ruxolitinib Impurity 9; Ruxolitinib Impurity 11; Ruxolitinib Lmpurity3; (R)-3-Cyclopentyl-3-(4-(7-(Hydroxymethyl)-7H-Pyrrolo[2,3-D]Pyrimidin-4-yl)-1H-Pyrazol-1-yl)Propanenitrile
- CAS编号1236033-03-6
- MFCD编号:MFCD28386855
- FDA UNII编号:8JZT65KUW4
- 分子式:C18H20N6O分子量:336.4
- 产品CID: 340486
- 产品分类分析化学 → 标准品 → 药典标准品和杂质标准品
物理性质
MSDS等安全信息
上下游产品
(3R)-3-cyclopentyl-3-[4-(7-[2-(trimethylsilyl)ethoxy]methyl-7H-pyrrolo[2,3-d]-pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile ruxolitinib合成工艺路线路线简述
📜(Betar)-Beta-环戊基-4-[7-[[2-(三甲基硅烷基)乙氧基]甲基]-7H-吡咯并[2,3-D]嘧啶-4-基]-1H-吡唑-1-丙腈置于三氟化硼乙醚,水体系中,用 乙腈 用作溶剂,化学反应生成1H-吡唑-1-丙腈,β-环戊基-4-[7-(羟基甲基)-7H-吡咯并[2,3-D]嘧啶-4-基]-,(βr)-
参考文献:Processes For Preparing Jak Inhibitors And Related Intermediate Compounds
标题:Processes For Preparing Jak Inhibitors And Related Intermediate Compounds
摘要:本发明涉及制备手性取代吡唑基吡咯并[2,3-D]嘧啶的公式iii的过程,以及相关的合成中间体化合物.这些手性取代吡唑基吡咯并[2,3-D]嘧啶可用作抑制janus激酶家族蛋白酪氨酸激酶(jaks)的药物,用于治疗炎症性疾病,骨髓增生性疾病和其他疾病.
海关参考信息
- 2905110000-甲醇
2926909090-其他腈基化合物 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-10562904-B2
优先权日:2015-12-31
标 题:Synthesis process of ruxolitinib
发明人：ZHANG XIQUAN; ZHANG AIMING; ZHOU ZHOU; YANG LEILEI; YAO HUADONG; ZHU XUEYAN; WANG HUBO
权利人:CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD
摘要:The present application falls within the field of drug synthesis, and in particular, the present application relates to a method for preparing ruxolitinib, and a method for preparing the intermediate and relevant intermediates used. The method comprises reacting a compound of formula II with a compound of formula IV or a salt thereof to obtain a compound of formula III, and then subjecting the compound of formula III to an acyl halogenation reaction, an amidation reaction, and a reaction dehydrating an amide to form a cyano group or removing the protecting group to prepare ruxolitinib. The method has the characteristics of brief steps, a high stereoselectivity, a high utilization ratio of atoms, mild reaction conditions and convenient post treatment. The method avoids using expensive asymmetric reaction catalysts, and is suitable for industrial production.
专利号:US-2019023712-A1
优先权日:2015-12-31
标题 :Synthesis process of ruxolitinib
专利号:EP-3398952-B1
优先权日:2015-12-31
标题 :Synthesis process of ruxolitinib
专利号:WO-2017114461-A1
优先权日:2015-12-31
标 题 :Synthesis process of ruxolitinib
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
参考标题:Enantioselective Synthesis Of Janus Kinase Inhibitor Incb018424 Via An Organocatalytic Aza-Michael Reaction作者:Qiyan Lin,David Meloni,Yongchun Pan,Michael Xia,James Rodgers,Stacey Shepard,Mei Li,Laurine Galya,Brian Metcalf,Tai-Yuen Yue,Pingli Liu,Jiacheng Zhou |发布日期:2009.5.7
摘要:An Enantioselective Synthesis Of Incb018424 Via Organocatalytic Asymmetric Aza-Michael Addition Of Pyrazoles (16 Or 20) To (E)-3-Cyclopentylacrylaldehyde (23) Using Diarylprolinol Silyl Ether As The Catalyst Was Developed. Michael Adducts (R)-24 And (R)-27 Were Isolated In Good Yield And High Ee And Were Readily Converted To Incb018424.
合成参考文献
参考DOI号:10.1021/ol900350k
📝 需求与反馈
尽可能描述清楚需求与问题信息
